SpringWorks came to life with a clutch of drugs licensed from Pfizer, but won't rely on Pfizer’s shelves forever, with plans to boost its pipeline by partnering with other biopharmas and academic institutions.
Scientists from China, South Korea and the U.S. succeeded in safe correction of the gene mutation in early human embryos that results in hypertrophic cardiomyopathy by using CRISPR/Cas9 genome editing technique.